newsfilter
← Earnings
Earnings Releases·

Avalyn Pharma — Third Quarter 2026 Earnings Summary

  • Reported a net loss of $29.7 million for Q3 2026, an increase from $23.6 million in the prior year period, driven by R&D expenses rising to $25.5 million and G&A expenses doubling to $7.6 million.
  • Cash, cash equivalents, and marketable securities increased significantly to $386.6 million as of September 30, 2026, from $138.4 million at year-end 2025, extending the cash runway into 2029.
  • Management anticipates a transformational 2027 with topline data expected across all three programs: AP01 (MIST Phase 2b) and AP03 (Phase 1) in the second half of 2027, and AP02 (AURA Phase 2) in late 2027.
  • Strategic portfolio advancement includes ongoing global Phase 2 trials for AP01 and AP02, the initiation of a Phase 1 study for the combination therapy AP03, and the September appointment of former FDA leader Robert J. Meyer to the Board.
Company
AVALYN PHARMA INC
Sector
Healthcare
Industry
Biotechnology